rheumatology
Autoinflammatory diseases

Hope dries up for abatacept in Sjögren’s syndrome

Despite showing promising results in Sjögren’s syndrome in open-label studies, abatacept has failed to show a significant benefit in the condition when compared with placebo in a randomised controlled trial. A Dutch study that compared 24 weeks of treatment with abatacept with placebo in 80 adults with primary Sjögren’s syndrome found no significant difference in ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic